Growth Metrics

Jazz Pharmaceuticals (JAZZ) Cash from Investing Activities (2016 - 2026)

Jazz Pharmaceuticals has reported Cash from Investing Activities over the past 16 years, most recently at -$372.2 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 92.54% year-over-year to -$372.2 million; the TTM value through Dec 2025 reached -$1.5 billion, down 197.11%, while the annual FY2025 figure was -$1.5 billion, 197.11% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$372.2 million at Jazz Pharmaceuticals, down from -$327.8 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $737.1 million in Q1 2021 and troughed at -$5.9 billion in Q2 2021.
  • A 5-year average of -$392.0 million and a median of -$129.0 million in 2022 define the central range for Cash from Investing Activities.
  • Biggest five-year swings in Cash from Investing Activities: surged 1326.92% in 2021 and later crashed 5538.82% in 2024.
  • Year by year, Cash from Investing Activities stood at -$10.1 million in 2021, then crashed by 3114.21% to -$324.4 million in 2022, then soared by 131.38% to $101.8 million in 2023, then plummeted by 289.87% to -$193.3 million in 2024, then plummeted by 92.54% to -$372.2 million in 2025.
  • Business Quant data shows Cash from Investing Activities for JAZZ at -$372.2 million in Q4 2025, -$327.8 million in Q3 2025, and -$641.0 million in Q2 2025.